Browse the evidence

Patients treated with GLP-1 based therapies must increase protein intake to 1–1.5 g/kg bodyweight/day and engage in resistance training to mitigate the loss of lean body mass (LBM) and prevent sarcopenic obesity.

If you are taking a GLP-1 medication like Ozempic or Wegovy, you must eat more protein than the standard recommendation. Aim for 1 to 1.5 grams of protein per kilogram of your body weight every day. Additionally, you must lift weights or do resistance exercises at least twice a week. This combination is the only proven way to stop your body from eating its own muscle while you lose fat.

Whey protein supplementation (20-40 g/day) combined with resistance training preserves lean body mass and improves strength during GLP-1RA-induced weight loss.

Aim for 1.2-2.0 grams of protein per kilogram of body weight daily. Use whey protein shakes (20-40g) to help meet this goal, especially if you struggle to eat enough solid food. Combine this with resistance training to protect your muscles.

Omega-3 fatty acid supplementation (≥1 g/day) supports muscle quality, cardiovascular health, and reduces inflammation during GLP-1RA treatment.

Take at least 1 gram of Omega-3 fatty acids daily. This helps protect your heart, reduces inflammation, and may support muscle quality while you lose weight.

In patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, achieving MASH resolution and fibrosis improvement is significantly associated with greater reductions in body weight, improved glycemic control (HbA1c), and normalization of liver fat.

If you have MASH with fibrosis, achieving significant weight loss, better blood sugar control, and normalizing liver fat are key steps toward resolving the disease. Tirzepatide, taken once weekly and titrated up from 2.5mg to 5-15mg over several months, has been shown to facilitate these metabolic changes, which in turn drive histological improvement in the liver.

Retatrutide (4-12 mg weekly) produces early, sustained changes in appetite and eating behaviors (reduced hunger, increased satiety, smaller portions) within 8 weeks, leading to significant weight loss and improved physical/emotional well-being in adults with obesity.

If you have obesity or overweight with health complications, retatrutide (4-12mg weekly) significantly reduces hunger and increases fullness within weeks, leading to substantial weight loss (up to 24%) and improved energy/mobility. It addresses the biological barriers to lifestyle changes that often cause failure with diet/exercise alone. Expect some frustration if results are slower than hoped or side effects occur, but the behavioral shift in eating is a key benefit.

Resistance training preserves or increases lean muscle mass and improves muscle quality in adults with obesity, even when combined with energy-restricted diets or obesity management medications that typically cause lean mass loss.

Incorporate resistance training into your routine to protect your muscle mass. This is especially important if you are dieting or taking weight-loss medications, as these can cause muscle loss. Focus on strength and function rather than just size.

GLP-1/GIP/Glucagon triple-agonists (e.g., Retatrutide) produce superior weight loss (up to 24.2%) compared to dual-agonists and GLP-1 monotherapies by simultaneously reducing food intake and increasing energy expenditure.

Retatrutide is a once-weekly injection that targets three hormones (GLP-1, GIP, Glucagon) to maximize weight loss. In clinical trials, doses up to 12mg resulted in an average 24.2% body weight loss over 48 weeks, outperforming single-hormone drugs. While it causes mild gastrointestinal side effects, the significant weight reduction makes it a highly effective option for obesity management.

Exercise training, particularly aerobic interval training and cardiac rehabilitation, is a Class I recommendation that counteracts skeletal muscle wasting and improves functional capacity in heart failure patients.

Engage in supervised exercise programs, such as cardiac rehabilitation or aerobic interval training. These are strongly recommended for heart failure patients to maintain muscle strength and improve how you feel.

Post-exercise supplementation with 40g of whey protein significantly enhances lower-body strength adaptations (leg 1-RM) in untrained adults performing low-volume intra-session concurrent training, compared to an isocaloric placebo.

If you are new to exercise and doing a mix of cardio and weights, drinking 40g of whey protein right after your workout can help you build more leg strength than if you drank a calorie-matched sugar drink. This is particularly useful if you struggle to eat a full meal immediately after training.

Consuming beef with a favorable fatty acid profile (higher monounsaturated fatty acids, lower saturated fatty acids) significantly improves serum lipid parameters (total cholesterol, LDL, non-HDL, and atherogenic indexes) compared to consuming standard commercial beef, even when the high-MUFA beef has higher total fat content.

If you eat beef, choosing cuts with a better fatty acid profile (higher in monounsaturated fats like oleic acid and lower in saturated fats) can lead to better cholesterol levels compared to standard commercial beef. You don't need to eliminate beef; you can optimize your choice. In this study, eating 120g of this specific beef 3 times a week for just 2 weeks improved LDL and other lipid markers significantly compared to standard beef.

Bariatric surgery is recommended for eligible patients with noncirrhotic MASLD to achieve sustained weight reduction and remission of type 2 diabetes.

If you have severe obesity and MASLD, discuss bariatric surgery with your doctor. It can lead to significant weight loss and remission of type 2 diabetes, reducing your risk of liver and heart disease.

Prevention of GLP-1RA-induced muscle loss requires a multimodal strategy combining resistance exercise, high protein intake (1.2-1.6 g/kg/day), and potentially specific supplements (BCAA, Creatine, Vitamin D).

To keep your muscles while losing weight on GLP-1s, lift weights 2-3 times a week and eat 1.2-1.6 grams of protein per kg of your body weight every day. Spread this protein across 3 meals. Consider adding creatine or Vitamin D if your diet is lacking.

Dual and triple receptor agonists (e.g., tirzepatide, retatrutide, survodutide) demonstrate second-generation efficacy (≥15% weight loss) in clinical trials, offering expanded treatment options for obesity.

Newer medications like tirzepatide target multiple hormones (GLP-1 and GIP) to help you lose more weight than older drugs. Clinical trials show many people lose 15% or more of their body weight. These are taken once a week and are often used alongside lifestyle changes.

Combining GLP-1 receptor agonists with resistance and aerobic exercise training yields greater fat loss and better preservation of lean muscle mass compared to GLP-1 use alone.

If you are prescribed a GLP-1 medication for weight loss, do not rely on the drug alone. You must combine it with resistance and aerobic exercise. This combination is critical to ensure you lose fat rather than muscle, preserving your metabolic health and physical function.

A daily protein intake of approximately 1.6 grams per kilogram of body weight is recommended to spare lean body mass during weight loss induced by GLP-1 medications.

When losing weight on GLP-1s, aim to eat approximately 1.6 grams of protein for every kilogram of your body weight each day. This specific target helps protect your muscle mass from being lost along with the fat.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to semaglutide and dulaglutide in patients with type 2 diabetes and obesity.

For patients with T2DM or obesity, tirzepatide offers a potent once-weekly injection option that improves weight, blood sugar, and lipid profiles more effectively than some existing GLP-1 drugs. Due to potential gastrointestinal side effects, treatment should start at low doses and escalate slowly. Access may be limited by cost, requiring engagement with healthcare policymakers and insurers.

Remote delivery of a multicomponent weight management intervention (diet, physical activity, behavioral counseling) achieves clinically meaningful weight loss and maintenance in adults with intellectual disabilities, with 6-month weight loss superior to face-to-face home visits.

For adults with intellectual disabilities, remote weight management using video calls, diet apps, and fitness trackers is a viable and potentially superior alternative to in-person home visits. Success requires a supportive caregiver (study partner) and the use of simplified, pre-configured technology (iPads with specific apps). The intervention includes dietary guidance (Enhanced Stop Light Diet), physical activity goals, and monthly behavioral counseling, leading to significant weight loss and maintenance over 24 months.

Shortening inter-set rest intervals from 120 seconds to 60 seconds during resistance training increases cardiovascular, metabolic, and perceptual stress without reducing total volume-load, thereby providing a more potent stimulus for hypertrophy.

To maximize muscle growth, try reducing your rest between sets to 60 seconds. This increases the metabolic stress (lactate, heart rate, perceived effort) which is linked to hypertrophy, without sacrificing the amount of weight you lift. You do not need to rest 2 minutes; 1 minute is sufficient to maintain performance while boosting the hormonal and metabolic response.

A plant-based, low-fat diet (75% carb, 10% fat) significantly reduces ad libitum energy intake compared to an animal-based, low-carbohydrate diet (10% carb, 75% fat) in adults without diabetes, primarily due to lower energy density and higher fiber content.

If you want to naturally eat fewer calories without counting them, try a plant-based, low-fat diet rich in fiber. In this study, participants ate over 700 fewer calories per day on a high-carb, low-fat diet compared to a high-fat, low-carb diet, largely because the high-carb food had lower energy density. Focus on whole plant foods like vegetables, fruits, and grains, and limit added fats to see if this helps you eat less spontaneously.

In individuals with Type 2 Diabetes Mellitus, a 15-minute post-meal walk at ~60% VO2peak significantly reduces daily insulin exposure (AUC) and post-prandial glucose/insulin spikes, whereas an 8-hour time-restricted eating (TRE) window alone does not significantly alter total daily blood glucose compared to a 12-hour window.

If you have Type 2 Diabetes, focus on taking a 15-minute walk after your main meals rather than strictly restricting your eating window to 8 hours for immediate glucose control. This specific timing of light-to-moderate intensity walking significantly lowers insulin requirements and reduces post-meal blood sugar spikes, which helps manage daily glycemic variability.

Prescription weight loss medications (oral or injectable) combined with lifestyle interventions result in additional weight loss compared to lifestyle interventions alone, with newer emergent medications demonstrating up to 12.4% weight loss over 68 weeks.

If you have obesity, lifestyle changes are the foundation, but adding prescription medication can significantly boost your weight loss results (3-12%+). Don't let fear of needles or side effects stop you from discussing these options with your doctor; many patients find the benefits outweigh the manageable risks, and doctors often overestimate this fear.

Combining GLP-1 receptor agonists with resistance training and/or specific nutritional strategies (e.g., higher protein, ketogenic therapy) preserves fat-free mass and muscle strength better than pharmacotherapy alone.

To prevent muscle loss while on GLP-1s, consider combining your medication with resistance training and a diet that supports muscle retention, such as one higher in protein or potentially ketogenic, under medical supervision.

Obesity medications (OMs) such as semaglutide and tirzepatide cause significant weight loss but also result in lean mass loss, necessitating targeted nutritional and exercise interventions to preserve skeletal muscle.

OMs like semaglutide and tirzepatide are highly effective for weight loss but can cause muscle loss. To counter this, eat enough protein (0.8-1.5 g/kg/day depending on your age/health) and do resistance exercises. This helps protect your muscle while you lose fat.

In a comprehensive digital obesity service using Tirzepatide, consistent weekly behavioral engagement (weight tracking and health coach communication) is the strongest predictor of 12-month adherence and weight loss, whereas hyper-engagement (intensive tracking frequency and high initial weight loss velocity) in the first month significantly increases the risk of program attrition.

To maximize your chances of long-term success with Tirzepatide in a digital program, prioritize consistent, moderate engagement over intense, rapid efforts. Track your weight weekly and communicate regularly with your health coach. Avoid the trap of 'hyper-engagement'—such as tracking daily or expecting massive weight loss in the first month—as this is strongly linked to dropping out of the program. Sustainable habits beat short bursts of intensity.